These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38763850)

  • 1. CRISPR/Cas9 screening: unraveling cancer immunotherapy's 'Rosetta Stone'.
    Chen B; Deng Y; Ren X; Zhao J; Jiang C
    Trends Mol Med; 2024 Aug; 30(8):736-749. PubMed ID: 38763850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CRISPR System and Cancer Immunotherapy Biomarkers.
    Balan V; Wang J
    Methods Mol Biol; 2020; 2055():301-322. PubMed ID: 31502158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
    Wu HY; Cao CY
    Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
    Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
    J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy.
    Potts MA; McDonald JA; Sutherland KD; Herold MJ
    Eur J Immunol; 2020 Dec; 50(12):1871-1884. PubMed ID: 33202035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy.
    Liu Z; Shi M; Ren Y; Xu H; Weng S; Ning W; Ge X; Liu L; Guo C; Duo M; Li L; Li J; Han X
    Mol Cancer; 2023 Feb; 22(1):35. PubMed ID: 36797756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer.
    Wang SW; Gao C; Zheng YM; Yi L; Lu JC; Huang XY; Cai JB; Zhang PF; Cui YH; Ke AW
    Mol Cancer; 2022 Feb; 21(1):57. PubMed ID: 35189910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment.
    Liu B; Saber A; Haisma HJ
    Drug Discov Today; 2019 Apr; 24(4):955-970. PubMed ID: 30849442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clustered Regularly Interspaced Short Palindromic Repeats and Clustered Regularly Interspaced Short Palindromic Repeats-Associated Protein 9 System: Factors Affecting Precision Gene Editing Efficiency and Optimization Strategies.
    Li J; Tang C; Liang G; Tian H; Lai G; Wu Y; Liu S; Zhang W; Liu S; Shao H
    Hum Gene Ther; 2023 Dec; 34(23-24):1190-1203. PubMed ID: 37642232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics.
    Bhat AA; Nisar S; Mukherjee S; Saha N; Yarravarapu N; Lone SN; Masoodi T; Chauhan R; Maacha S; Bagga P; Dhawan P; Akil AA; El-Rifai W; Uddin S; Reddy R; Singh M; Macha MA; Haris M
    J Transl Med; 2022 Nov; 20(1):534. PubMed ID: 36401282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
    Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
    Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering T Cells Using CRISPR/Cas9 for Cancer Therapy.
    Zhang X; Cheng C; Sun W; Wang H
    Methods Mol Biol; 2020; 2115():419-433. PubMed ID: 32006414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges.
    Chen M; Xu J; Zhou Y; Zhang S; Zhu D
    Brief Funct Genomics; 2020 May; 19(3):183-190. PubMed ID: 31788683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer.
    Zhang H; Qin C; An C; Zheng X; Wen S; Chen W; Liu X; Lv Z; Yang P; Xu W; Gao W; Wu Y
    Mol Cancer; 2021 Oct; 20(1):126. PubMed ID: 34598686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
    Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
    Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide CRISPR screens for the identification of therapeutic targets for cancer treatment.
    Xue VW; Wong SCC; Cho WCS
    Expert Opin Ther Targets; 2020 Nov; 24(11):1147-1158. PubMed ID: 32893711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment.
    Xu X; Liu C; Wang Y; Koivisto O; Zhou J; Shu Y; Zhang H
    Adv Drug Deliv Rev; 2021 Sep; 176():113891. PubMed ID: 34324887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.